Genprex Research Links Low TROP2 Expression to Reqorsa Resistance in Lung Cancer
Bitget2026/11/04 12:06- Genprex identified TROP2 expression as a potential predictor of response to its experimental Reqorsa gene therapy for non-small cell lung cancer.
- Low TROP2 expression was associated with treatment resistance in preclinical models, supported by analysis of pretreatment tumor biopsies from clinical trial patients.
- Results will be presented Nov. 18, 2026, at the EORTC-NCI-AACR Symposium in Barcelona, Spain.
- The findings could guide patient selection, but further research and prospective clinical evaluation are needed to establish TROP2's predictive value.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
Bernstein Downgrades Nvidia Rating and Target Price
Google (GOOGL.US) DeepMind launches AlphaGenome 2: Capable of decoding DNA cells with nearly double the mutation identification capacity
Google DeepMind has released its AI model AlphaGenome 2, which is trained on maps of over 100 millions of cells and has nearly double the ability of its predecessor in identifying gene expression variations.
The White House did not intervene in the decision-making of Nvidia's board of directors.
Crypto prices
More
